Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Payables: 2016-2024

Historic Payables for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $58.3 million.

  • Tg Therapeutics' Payables rose 10.78% to $112.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $438.6 million, marking a year-over-year increase of 36.79%. This contributed to the annual value of $58.3 million for FY2024, which is 51.53% up from last year.
  • Tg Therapeutics' Payables amounted to $58.3 million in FY2024, which was up 51.53% from $38.5 million recorded in FY2023.
  • Tg Therapeutics' Payables' 5-year high stood at $58.3 million during FY2024, with a 5-year trough of $37.0 million in FY2020.
  • Its 3-year average for Payables is $46.3 million, with a median of $42.0 million in 2022.
  • In the last 5 years, Tg Therapeutics' Payables dropped by 18.08% in 2022 and then spiked by 51.53% in 2024.
  • Tg Therapeutics' Payables (Yearly) stood at $37.0 million in 2020, then soared by 38.58% to $51.3 million in 2021, then dropped by 18.08% to $42.0 million in 2022, then decreased by 8.44% to $38.5 million in 2023, then soared by 51.53% to $58.3 million in 2024.